Acacia Research Reports Second Quarter 2023 Financial Results

Acacia Research Reports Second Quarter 2023 Financial Results

NEW YORK–(BUSINESS WIRE)–
Acacia Research Corporation (Nasdaq: ACTG) (“Acacia” or the “Company”) today reported financial results for the three and six months ended June 30, 2023.

Key Business Highlights

  • On July 13, 2023, completed its recapitalization transaction with Starboard Value LP, and as part of this transaction:

    • Starboard converted 350,000 shares of Acacia’s Series A Convertible Preferred Stock into 9,616,746 shares of Common Stock, including 27,704 shares of Common Stock issued in respect of accrued and unpaid dividends.

    • Starboard also exercised 31,506,849 of the Company’s Series B Warrants (the “Series B Warrants”) through a combination of a “Note Cancellation” and a “Limited Cash Exercise” for an aggregate total of 31,506,849 shares of Common Stock

    • Pursuant to the Series B Warrants exercise, the Company cancelled $60 million aggregate principal amount of senior secured notes held by Starboard and received aggregate gross proceeds of approximately $55 million.

    • As a result of the Recapitalization Transactions, Starboard holds 61,123,595 shares of Common Stock, representing approximately 61.2% of Acacia’s Common Stock

  • Generated $7.9 million in consolidated revenue for the quarter compared to $16.7 million in revenue in the second quarter of 2022.

  • Recorded $1.4 million of net realized and unrealized losses during the quarter.

 

Second Quarter 2023 Financial Highlights

(In millions, except per share data)

 

 

Three Months Ended June

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

(unaudited)

 

(unaudited)

Intellectual property operations

$

0.4

 

 

$

8.1

 

 

$

4.6

 

 

$

10.7

 

Industrial operations

 

7.5

 

 

 

8.7

 

 

 

18.1

 

 

 

19.5

 

Total revenues

$

7.9

 

 

$

16.7

 

 

$

22.7

 

 

$

30.2

 

Operating loss

$

(12.5

)

 

$

(5.7

)

 

$

(21.9

)

 

$

(14.2

)

Unrealized gains (losses) 1

$

6.6

 

 

$

(57.6

)

 

$

10.0

 

 

$

(229.9

)

Realized (losses) gains

$

(8.0

)

 

$

11.5

 

 

$

(9.4

)

 

$

78.4

 

Non-cash derivative liability (losses) gains 2

$

(9.9

)

 

$

(35.1

)

 

$

6.7

 

 

$

(7.0

)

GAAP Net loss

$

(18.8

)

 

$

(61.5

)

 

$

(9.3

)

 

$

(134.8

)

GAAP Diluted loss per share

$

(0.36

)

 

$

(1.44

)

 

$

(0.26

)

 

$

(3.06

)

 

 

 

 

 

 

 

 

1 Unrealized gains and (losses) are related to the change in fair value of equity securities as of the end of the reported period.

2 The non-cash derivative liability gains and (losses) are related to the change in fair value of Acacia’s Series A and B warrants and embedded derivatives.

Martin D. McNulty, Jr. “MJ”, Interim Chief Executive Officer, stated, “We successfully completed the recapitalization transaction with Starboard Value LP, which follows on the heels of our transformation of Acacia by revamping our processes for identifying and pursuing transactions and establishing the framework to support acquisitions of both public and private companies. I am confident that we have the right team and processes in place, along with incentives to create value. Our pipeline of acquisition targets has grown and matured, and we are methodically advancing specific opportunities.”

“We have a number of late-stage targets in our pipeline, and we are optimistic about our prospects,” continued Mr. McNulty. “Predicting the specific timing of deals remains impossible, and we maintain rigor in our processes, but I am confident in the progress. Additionally, we have successfully enhanced operations at Printronix.”

Second Quarter 2023 Financial Summary:

  • Total revenues were $7.9 million, compared to $16.7 million in the same quarter last year.

    • Printronix generated $7.5 million in revenue during the quarter, compared to $8.7 million in the same quarter last year.

    • The Intellectual Property business generated $394,000 in licensing and other revenue during the quarter, compared to $8.1 million in the same quarter last year.

  • General and administrative expenses were $9.4 million, compared to $10.7 million in the same quarter of last year due to the decrease in personnel costs and compensation costs related to reduced headcount.

  • Operating loss of $12.5 million, compared to an operating loss of $5.7 million in the same quarter of last year, with the increase due to lower revenues generated.

    • Printronix contributed $513,000 in operating loss which included $774,000 of non-cash depreciation and amortization expense.

  • GAAP net loss of $18.8 million, or a loss of $0.36 per diluted share, compared to GAAP net loss of $61.5 million, or $1.44 per diluted share, in the second quarter of last year.

    • Net loss included $8.0 million in realized losses and $6.6 million in unrealized gains related to the increase in share price of certain holdings.

    • The Company recognized non-cash expense of $9.9 million related to the change in fair value of the Starboard Series B warrants and embedded derivative liabilities in the Series A Preferred Stock. The change in fair value was primarily due to the increase in stock price.

    • The second quarter included $2.4 million in non-recurring charges related to severance, legal and other professional fees associated with the separation from our former CEO, and other non-recurring charges.

Life Sciences Portfolio

Acacia has generated $504.3 million in proceeds from sales and royalties of the Life Sciences Portfolio through June 30, 2023, which was purchased for an aggregate price of $301.4 million. At the end of the second quarter, the remaining positions in the Life Sciences Portfolio represent $67.9 million in book value:

  • Acacia continues to hold 33.0 million shares of Arix Bioscience plc (LSE: ARIX), valued at $42.2 million.

  • Acacia holds interests in three private companies, valued at an aggregate of $25.7 million, net of non-controlling interest, including a 26% interest in Viamet Pharmaceuticals, Inc., a 18% interest in AMO Pharma, and a 4% interest in NovaBiotics. Values are based on cost or equity accounting.

Balance Sheet and Capital Structure

  • Cash, cash equivalents and equity investments measured at fair value totaled $408 million at June 30, 2023 compared to $349.4 million at December 31, 2022. The increase in cash was primarily due to the completed Rights Offering and concurrent Private Rights Offering.

  • Equity securities without readily determinable fair value totaled $5.8 million at June 30, 2023, which amount was unchanged from December 31, 2022.

  • Investment securities representing equity method investments totaled $19.9 million at June 30, 2023 (net of noncontrolling interests), which amount was unchanged from December 31, 2022. Acacia owns 64% of MalinJ1, which results in a 26% ownership stake in Viamet Pharmaceuticals, Inc. for Acacia.

  • Total indebtedness, which represents the Senior Secured Notes issued to Starboard, was $60.5 million at June 30, 2023.

  • The Company’s book value totaled $335.4 million, or $5.71 per share, at June 30, 2023, compared to $269.3 million, or $6.19 per share, at December 31, 2022. Acacia’s book value reflects the balance of the warrant and embedded derivative liabilities, which were subsequently extinguished on July 13, 2023 as part of the recapitalization transaction. An as adjusted book value analysis can be found below.

  • Assuming the full impact of the recent completed Recapitalization Transactions with Starboard, as adjusted to give effect to the transactions as if they had been completed as of June 30, 2023, Acacia’s adjusted book value would decline to $502.2 million, or $5.03 per share.

As Adjusted Book Value and Changes to Derivative Valuations

At June 30, 2023, book value was $335.4 million and there were 58.8 million shares of common stock outstanding, for a book value per share of $5.71, compared to $269.3 million, or $6.19 per share at December 31, 2022. The decrease in book value per share since December 31, 2022 is due to the $5.25 per share price of shares issued in the Rights Offering and concurrent private Rights Offering. Total liabilities for warrants and convertible preferred stock to be eliminated upon exercise or expiration of all such warrants and convertible preferred stock were $94.9 million at June 30, 2023.

Book value and book value per share calculations are performed in accordance with GAAP. The calculation of book value under GAAP requires the Company to reflect the impact of liabilities associated with issuances of shares related to the exercise of the Company’s Series B warrants and conversion of the Company’s Series A preferred stock. The value of those liabilities varies over time based on fluctuations in the trading price of the Common Stock. The previously announced agreement reached with Starboard to streamline the Company’s capital structure and strengthen its financial position (the “recapitalization transactions”) eliminated all of these instruments and the associated liabilities.

Management believes that providing investors with a presentation of adjusted book value and adjusted book value per share that reflect the impact of the completion of each component of the recapitalization transactions (as adjusted to give effect to the transaction as if they had been completed as of June 30, 2023) may assist investors in understanding the Company’s financial condition and capital structure (see below for a description of the material components of the recapitalization transactions). However, these adjusted calculations have limitations and should not be considered in isolation or as a substitute for the actual book value and book value per share amounts reflected in the Company’s balance sheet at June 30, 2023. These adjusted calculations have been presented for informational purposes only and do not purport to project the future financial position of the Company.

Book value at June 30, 2023 reflects the following:

  • $60.0 million in principal amount of Senior Secured Notes issued to Starboard;

  • $35.0 million in face value ($23.2 million in book value) of Series A preferred stock issued to Starboard; and

  • $94.9 million of warrants and embedded derivative liabilities associated with all preferred stock and warrants held by Starboard.

In connection with the recently completed recapitalization transactions with Starboard, which occurred on July 13, 2023:

  • In the first quarter of 2023, Starboard purchased 15.0 million new shares in a private Rights Offering, at $5.25 per share, for total proceeds of $78.8 million;

  • $35.0 million in face value of Series A preferred stock was eliminated, and 9.6 million shares of common stock were issued in Q3 2023;

  • $60.5 million of liabilities attributable to the Senior Secured Notes were converted into equity, and Starboard invested an additional $55.0 million in cash related to the Series B warrant exercise, and 31.5 million shares of common stock was issued in Q3 2023;

  • $94.9 million of total warrant and embedded derivative liabilities attributable to the Series B warrants and Series A preferred stock was eliminated in Q3 2023;

  • Acacia paid Starboard a total of $66.0 million, representing a negotiated settlement of the foregone time value of the Series B warrants and the Series A preferred stock (which amount was paid through a reduction in the exercise price of the Series B Warrants) in Q3 2023; and

  • Acacia incurred approximately $250,000 in transaction costs associated with the consummation of the recapitalization transactions.

The completion of the recapitalization transactions resulted in an incremental $166.8 million increase in book value, and an incremental 41.1 million increase in shares outstanding. Adjusted book value as adjusted to give effect to the transaction as if it had been completed on June 30, 2023 would be $502.2 million, and diluted shares outstanding would be 99.9 million, resulting in adjusted book value per share of $5.03 at June 30, 2023.

See Attachment A which illustrates the sequential impact of each component of the recapitalization transactions on book value and book value per share as adjusted to give effect to the transactions as if they had been completed on June 30, 2023.

In previous quarterly reports, prior to the approval of the recapitalization transactions, Acacia had presented a similar adjusted book value per share calculation assuming the exercise of all outstanding Series A and Series B warrants, as well as the conversion of the Series A preferred stock. This resulted in a reported adjusted book value per share of $5.10 at March 31, 2023, $5.18 at December 31, 2022, $5.22 at September 30, 2022, $5.87 at June 30, 2022, $5.91 at March 31, 2022 and $6.51 at December 31, 2021. The $5.25 per share cash exercise feature of 68.5 million Series B warrants expired on October 28, 2022 and 5.0 million $3.65 per share Series A warrants were exercised on November 1, 2022.

Investor Conference Call

The Company will host a conference call today, August 3, 2023 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

To access the live call, please dial 888-506-0062 (U.S. and Canada) or 973-528-0011 (international) and if requested, reference conference ID 435061. The conference call will also be simultaneously webcasted on the investor relations section of the Company’s website at http://www.acaciaresearch.com under Events & Presentations. Following the conclusion of the live call, a replay of the webcast will be available on the Company’s website for at least 30 days.

About the Company

Acacia is an opportunistic capital platform with a strategy to purchase businesses based on the differentials between public and private market valuations. Acacia leverages its (i) disciplined focus on identifying opportunities where it can be an advantaged buyer, initiate a transaction opportunity spontaneously, avoid a traditional sale process and complete the purchase of a business, division or other asset at an attractive price, (ii) willingness to invest across industries and in off-the-run, often misunderstood assets that suffer from a complexity or multi-factor discount, (iii) relationships and partnership abilities across functions and sectors, and (iv) strong expertise in corporate governance and operational transformation. Acacia seeks to identify opportunities where it believes it is an advantaged buyer, where it can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to Acacia’s unique capabilities, relationships or expertise, or Acacia believes the target would be worth more to it than to other buyers. Acacia operates its businesses based on three key principles of people, process and performance and has built a management team with demonstrated expertise in research, transactions and execution, and operations and management. Additional information about Acacia and its subsidiaries is available at www.acaciaresearch.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations and speak only as of the date hereof. This news release attempts to identify forward-looking statements by using words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” or other forms of these words or similar words or expressions or the negative thereof, although not all forward-looking statements contain these terms. The Company’s actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the Company’s ability to successfully implement its strategic plan, changes to our relationship and arrangements with Starboard Value LP, the ability to successfully identify and complete strategic acquisitions of businesses, divisions, and/or assets, the ability to successfully develop licensing programs and attract new business, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, the decrease in demand for Printronix’ products, general economic conditions, and the success of the Company’s investments. The Company’s Annual Report on Form 10-K, and other SEC filings discuss these and other important risks and uncertainties that may affect the Company’s business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

The results achieved by the Company in prior periods are not necessarily indicative of the results to be achieved by us in any subsequent periods. It is currently anticipated that the Company’s financial results will vary, and may vary significantly, from quarter to quarter.

 

ACACIA RESEARCH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

 

June 30, 2023

 

December 31, 2022

 

(Unaudited)

 

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

355,188

 

 

$

287,786

 

Equity securities

 

52,853

 

 

 

61,608

 

Equity securities without readily determinable fair value

 

5,816

 

 

 

5,816

 

Equity method investments

 

30,934

 

 

 

30,934

 

Accounts receivable, net

 

6,267

 

 

 

8,231

 

Inventories

 

14,006

 

 

 

14,222

 

Prepaid expenses and other current assets

 

20,728

 

 

 

19,388

 

Total current assets

 

485,792

 

 

 

427,985

 

 

 

 

 

Property, plant and equipment, net

 

2,950

 

 

 

3,537

 

Goodwill

 

7,541

 

 

 

7,541

 

Other intangible assets, net

 

30,590

 

 

 

36,658

 

Leased right-of-use assets

 

910

 

 

 

2,005

 

Other non-current assets

 

6,925

 

 

 

5,202

 

Total assets

$

534,708

 

 

$

482,928

 

 

 

 

 

LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

5,789

 

 

$

6,036

 

Accrued expenses and other current liabilities

 

4,461

 

 

 

14,058

 

Accrued compensation

 

5,505

 

 

 

4,737

 

Royalties and contingent legal fees payable

 

579

 

 

 

699

 

Deferred revenue

 

1,022

 

 

 

1,229

 

Senior secured notes payable

 

60,450

 

 

 

60,450

 

Total current liabilities

 

77,806

 

 

 

87,209

 

 

 

 

 

Deferred revenue, net of current portion

 

535

 

 

 

568

 

Series A embedded derivative liabilities

 

12,881

 

 

 

16,835

 

Series B warrant liabilities

 

82,018

 

 

 

84,780

 

Long-term lease liabilities

 

898

 

 

 

1,873

 

Deferred income tax liabilities, net

 

125

 

 

 

742

 

Other long-term liabilities

 

1,858

 

 

 

1,675

 

Total liabilities

 

176,121

 

 

 

193,682

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

Series A redeemable convertible preferred stock, par value $0.001 per share; stated value $100 per share; 350,000 shares authorized, issued and outstanding as of June 30, 2023 and December 31, 2022; aggregate liquidation preference of $35,000 as of June 30, 2023 and December 31, 2022

 

23,154

 

 

 

19,924

 

 

 

 

 

Stockholders’ equity:

 

 

 

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding

 

 

 

 

 

Common stock, par value $0.001 per share; 300,000,000 shares authorized; 58,754,795 and 43,484,867 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

 

58

 

 

 

43

 

Treasury stock, at cost, 16,183,703 shares as of June 30, 2023 and December 31, 2022

 

(98,258

)

 

 

(98,258

)

Additional paid-in capital

 

738,712

 

 

 

663,284

 

Accumulated deficit

 

(316,121

)

 

 

(306,789

)

Total Acacia Research Corporation stockholders’ equity

 

324,391

 

 

 

258,280

 

 

 

 

 

Noncontrolling interests

 

11,042

 

 

 

11,042

 

 

 

 

 

Total stockholders’ equity

 

335,433

 

 

 

269,322

 

 

 

 

 

Total liabilities, redeemable convertible preferred stock, and stockholders’ equity

$

534,708

 

 

$

482,928

 

 

ACACIA RESEARCH CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

Intellectual property operations

$

394

 

 

$

8,062

 

 

$

4,570

 

 

$

10,677

 

Industrial operations

 

7,510

 

 

 

8,655

 

 

 

18,137

 

 

 

19,547

 

Total revenues

 

7,904

 

 

 

16,717

 

 

 

22,707

 

 

 

30,224

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenues – intellectual property operations

 

5,010

 

 

 

4,634

 

 

 

9,748

 

 

 

9,198

 

Cost of sales – industrial operations

 

3,933

 

 

 

4,592

 

 

 

9,153

 

 

 

8,784

 

Engineering and development expenses – industrial operations

 

205

 

 

 

145

 

 

 

421

 

 

 

335

 

Sales and marketing expenses – industrial operations

 

1,859

 

 

 

2,294

 

 

 

3,772

 

 

 

4,310

 

General and administrative expenses

 

9,426

 

 

 

10,722

 

 

 

21,466

 

 

 

21,775

 

Total costs and expenses

 

20,433

 

 

 

22,387

 

 

 

44,560

 

 

 

44,402

 

Operating loss

 

(12,529

)

 

 

(5,670

)

 

 

(21,853

)

 

 

(14,178

)

 

 

 

 

 

 

 

 

Other (expense) income:

 

 

 

 

 

 

 

Equity securities investments:

 

 

 

 

 

 

 

Change in fair value of equity securities

 

6,617

 

 

 

(57,647

)

 

 

9,960

 

 

 

(229,850

)

(Loss) gain on sale of equity securities

 

(7,999

)

 

 

11,498

 

 

 

(9,360

)

 

 

78,374

 

Earnings on equity investment in joint venture

 

 

 

 

42,085

 

 

 

 

 

 

42,085

 

Net realized and unrealized (loss) gain

 

(1,382

)

 

 

(4,064

)

 

 

600

 

 

 

(109,391

)

Change in fair value of the Series A and B warrants and embedded derivatives

 

(9,935

)

 

 

(35,146

)

 

 

6,716

 

 

 

(7,048

)

Gain (loss) on foreign currency exchange

 

15

 

 

 

(1,814

)

 

 

95

 

 

 

(2,627

)

Interest expense on Senior Secured Notes

 

(900

)

 

 

(1,859

)

 

 

(1,800

)

 

 

(4,460

)

Interest income and other, net

 

4,307

 

 

 

863

 

 

 

7,748

 

 

 

1,870

 

Total other (expense) income

 

(7,895

)

 

 

(42,020

)

 

 

13,359

 

 

 

(121,656

)

 

 

 

 

 

 

 

 

Loss before income taxes

 

(20,424

)

 

 

(47,690

)

 

 

(8,494

)

 

 

(135,834

)

 

 

 

 

 

 

 

 

Income tax benefit (expense)

 

1,645

 

 

 

200

 

 

 

(838

)

 

 

15,078

 

 

 

 

 

 

 

 

 

Net loss including noncontrolling interests in subsidiaries

 

(18,779

)

 

 

(47,490

)

 

 

(9,332

)

 

 

(120,756

)

 

 

 

 

 

 

 

 

Net income attributable to noncontrolling interests in subsidiaries

 

 

 

 

(14,013

)

 

 

 

 

 

(14,013

)

 

 

 

 

 

 

 

 

Net loss attributable to Acacia Research Corporation

$

(18,779

)

 

$

(61,503

)

 

$

(9,332

)

 

$

(134,769

)

 

 

 

 

 

 

 

 

Loss per share:

 

 

 

 

 

 

 

Net loss attributable to common stockholders – Basic

$

(21,155

)

 

$

(63,443

)

 

$

(13,962

)

 

$

(138,560

)

Weighted average number of shares outstanding – Basic

 

58,408,711

 

 

 

43,988,677

 

 

 

53,219,152

 

 

 

45,259,435

 

Basic net loss per common share

$

(0.36

)

 

$

(1.44

)

 

$

(0.26

)

 

$

(3.06

)

Net loss attributable to common stockholders – Diluted

$

(21,155

)

 

$

(63,443

)

 

$

(13,962

)

 

$

(138,560

)

Weighted average number of shares outstanding – Diluted

 

58,408,711

 

 

 

43,988,677

 

 

 

53,219,152

 

 

 

45,259,435

 

Diluted net loss per common share

$

(0.36

)

 

$

(1.44

)

 

$

(0.26

)

 

$

(3.06

)

 

Attachment A

The following table illustrates the sequential impact of each component of the recapitalization transactions on book value as of June 30, 2023 on an as adjusted basis to give effect to each such component of the recapitalization as if it had been completed as of June 30, 2023:

As Adjusted Book Value at 6/30/2023

 

 

 

Series A Preferred Conversion

 

Series B Warrant Transactions

$ Millions

 

Basic

 

Series A

Preferred

Converted

Remove

Liability

6/30/2023

As

Adjusted

 

Senior

Secured Notes

Converted

Series B

Warrants

Exercised

Series B

Payment*

Transaction

Fees

Remove

Liability

6/30/2023

As

Adjusted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

355.2

 

 

 

 

355.2

 

 

 

(0.5

)

 

55.0

 

(66.0

)

 

(0.3

)

 

 

343.4

 

Equity securities at fair value

 

52.9

 

 

 

 

52.9

 

 

 

 

 

 

 

 

52.9

 

Equity securities without readily determinable fair value

 

5.8

 

 

 

 

5.8

 

 

 

 

 

 

 

 

5.8

 

Investment securities – equity method investments

 

30.9

 

 

 

 

30.9

 

 

 

 

 

 

 

 

30.9

 

Other assets

 

89.9

 

 

 

 

89.9

 

 

 

 

 

 

 

 

89.9

 

Total assets

 

534.7

 

 

534.7

 

 

 

(0.5

)

 

55.0

 

(66.0

)

 

(0.3

)

 

 

523.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notes payable

 

(60.5

)

 

 

 

(60.5

)

 

 

60.5

 

 

 

 

 

 

 

Warrant and derivative liabilities

 

(94.9

)

 

 

12.9

(82.0

)

 

 

 

 

 

 

82.0

 

 

Other liabilities

 

(20.8

)

 

 

 

(20.8

)

 

 

 

 

 

 

 

(20.8

)

Total liabilities

 

(176.1

)

 

12.9

(163.2

)

 

 

60.5

 

 

 

 

 

 

 

82.0

 

(20.8

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock

 

(23.2

)

 

23.2

 

 

 

 

 

 

 

 

$

 

Total liabilities and preferred stock

 

(199.3

)

 

23.2

12.9

(163.2

)

 

$

60.5

 

$

$

 

$

 

$

82.0

$

(20.8

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Book value – stockholders equity

 

335.4

 

 

23.2

12.9

371.5

 

 

 

60.0

 

 

55.0

 

(66.0

)

 

(0.3

)

 

82.0

 

502.2

 

Shares outstanding – basic

 

58.8

 

 

9.6

68.3

 

 

 

16.4

 

 

15.1

 

 

 

 

 

 

99.9

 

Book value per share

 

 

 

 

 

 

 

 

 

 

 

 

 

5.03

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KPIs:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

355.2

 

 

 

 

355.2

 

 

 

 

 

 

 

 

343.4

 

Cash and equity securities at fair value

 

408.0

 

 

 

 

408.0

 

 

 

 

 

 

 

 

396.3

 

Cash and equity securities at fair value / share

 

 

 

 

 

 

 

 

 

 

 

 

 

3.97

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*Note: This amount reflects the $66.0 million payment the Company subsequently made to Starboard in consideration for the early exercise of the Series B warrants, and convertible preferred stock.

 

 

 

 

 

 

 

 

 

 

 

Investor Contact:

FNK IR

Rob Fink, 646-809-4048

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Business Finance

MEDIA:

Tandem Diabetes Care Announces Technology Access Program to Provide Customers with Purchase Pathway to the Tandem Mobi System

Tandem Diabetes Care Announces Technology Access Program to Provide Customers with Purchase Pathway to the Tandem Mobi System

SAN DIEGO–(BUSINESS WIRE)–
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced a limited time offer for its Tandem Choice technology access program. This program provides new and renewing, eligible t:slim X2 Insulin Pump (t:slim X2) customers in the United States a pathway to ownership of the Tandem Mobi System (Tandem Mobi) for $199. The Tandem Mobi was recently cleared by the United States Food and Drug Administration to be used as a part of an automated insulin delivery system and a limited launch is expected to begin later this year with general availability in early 2024.

“Tandem Choice provides our customers time to decide which of our pump platforms best meets their needs and preferences, without having to delay experiencing the benefits of our Control-IQ technology,” said John Sheridan, president and chief executive officer. “Our #1 rated1 t:slim X2, designed for people who want the convenience of an integrated touchscreen device, and our new Tandem Mobi, which offers smartphone control and new wearability options, provides people living with diabetes the power of choice in customizing an automated insulin delivery system to meet their individual needs.”

About the Tandem Choice Program:

The Tandem Choice Program will be offered for a limited time at a discounted price of $199 to customers who purchased or purchase a t:slim X2 between July 1, 2023 and December 31, 2023. Customers who purchased a t:slim X2 before July 1, 2023 and have 12 months or more remaining on their existing warranty are also eligible to participate in the Tandem Choice program for the originally offered price of $999. Customers do not need to take action or make an election to participate at this time. Eligible customers can choose to participate in the program any time before December 31, 2024. If customers choose to participate they will be able to make a one-time switch from their t:slim X2 to the Tandem Mobi. For additional terms and conditions please visit:

https://www.tandemdiabetes.com/support/benefit-programs/pump-switch

About the t:slim X2

With approximately 440,000 customers worldwide, t:slim X2 is the #1 rated insulin pump by users1 and #1 in overall satisfaction by healthcare providers.2 It’s designed for people who want the convenience of an integrated touchscreen device and the flexibility to choose the components of their insulin delivery system, such as a continuous glucose monitoring (CGM) sensor or from more than 30 mix-and-match infusion set options, to fit a wider range of needs and lifestyles. The t:slim X2 is up to 38 percent smaller than other manufacturers’ durable insulin pumps, and still holds up to 300 units of insulin. It also offers users modern technology, such as the ability to deliver bolus insulin through the convenience of a compatible smartphone.3

About the Tandem Mobi

Testing the limits of pump miniaturization, Tandem Mobi is the world’s smallest durable automated insulin delivery system.4 Less than half the size of the t:slim X2 pump, it offers control from an iOS mobile app5 and features an on-pump button that provides an alternative option to phone control for bolusing insulin. Tandem Mobi can fit in a coin pocket, be clipped to clothing, or worn on-body with an adhesive sleeve (sold separately). Its 200-unit insulin cartridge is compatible with all existing Tandem-branded infusion sets, including a new five-inch tubing option made just for Tandem Mobi. Infusion sets allow users to temporarily disconnect from their pump for convenience and provide the flexibility of more than 30 mix-and-match infusion site and tubing length combinations.

About Control-IQ Advanced Hybrid Closed-Loop Technology

Both the t:slim X2 and the Tandem Mobi will be offered with Control-IQ technology, a hybrid-closed loop algorithm for use by people with type 1 diabetes age 6 and up. Control-IQ technology uses compatible CGM sensor values to predict glucose levels 30 minutes ahead and adjust insulin delivery every 5 minutes to help prevent highs and lows, while still allowing the user to manually bolus for meals. It can also deliver automatic correction boluses (up to one an hour) to help prevent hyperglycemia.6 Real-world data shows immediate and sustained glycemic improvements — including more time in range and better sleep.7 Results from major studies of Control-IQ technology were published by the New England Journal of Medicine in October 2019, August 2020, and March 2023.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.

Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the anticipated timing for the limited launch and subsequent general commercial availability of the Tandem Mobi system. These forward-looking statements are subject to numerous risks and uncertainties, including risks associated with the commercial launch of a new product, as well as manufacturing risks and risks related to adequate reimbursement coverage. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

1 dQ&A US Diabetes Connections Patient Panel Report, Q1 2020-Q2 2023 (Jan 2020-Jun 2023).

2 Seagrove Partners 2023 HCP Perspectives Report (N=265).

3 Bolus delivery from the t:connect mobile app requires a compatible smartphone model and operating system (sold separately). Only available to pump users who reside in the United States.

4 As of July 2023. Data on file, Tandem Diabetes Care.

5 The mobile app requires a compatible iPhone model and operating system (sold separately). Only available to pump users who reside in the United States. A complete list of compatible iPhones will be released closer to commercial availability.

6 If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled.

7Breton MD, Kovatchev BP. One-year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097.

Indications for Use

t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals six years of age and greater. The pump is intended for single patient use. The pump is indicated for use with U-100 insulin only.

Tandem Mobi insulin pump: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals six years of age and greater.

Control-IQ technology: Control-IQ technology is intended for use with a compatible iCGM (sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of type 1 diabetes mellitus in persons six years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with U-100 insulin only.

Responsible use of Control-IQ technology

Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their diabetes. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of a Tandem insulin pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The Tandem pump, and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

© 2023 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

Media Contact:

858-255-6388

[email protected]

Investor Contact:

858-366-6900

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Apps/Applications Mobile/Wireless Technology Medical Devices FDA Diabetes Health Technology Software Hardware Health

MEDIA:

Logo
Logo

Universal Display Corporation Announces Quarterly Cash Dividend of $0.35 per Share

Universal Display Corporation Announces Quarterly Cash Dividend of $0.35 per Share

EWING, N.J.–(BUSINESS WIRE)–Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that its Board of Directors approved a third quarter cash dividend of $0.35 per share on the Company’s common stock. The dividend is payable on September 29, 2023, to shareholders of record on September 15, 2023. The dividend reflects our expected continued cash flow generation, and commitment to return capital to our shareholders. Future dividends will be subject to Board approval.

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 6,000 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other company, brand or product names may be trademarks or registered trademarks.

All statements in this document that are not historical, such as those relating to the projected adoption, development and advancement of the Company’s technologies, and the Company’s expected results and future declaration of dividends, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2022. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

Follow Universal Display Corporation

Twitter

Facebook

YouTube

(OLED-C)

Universal Display Contact:

Darice Liu

[email protected]

[email protected]

+1 609-964-5123

KEYWORDS: United States North America New Jersey

INDUSTRY KEYWORDS: Consumer Electronics Technology Professional Services Semiconductor Research Nanotechnology Alternative Energy Energy Science Hardware Finance

MEDIA:

Logo
Logo

Loop Media Schedules Fiscal Third Quarter 2023 Conference Call for August 8, 2023 at 5:00 p.m. ET

Loop Media Schedules Fiscal Third Quarter 2023 Conference Call for August 8, 2023 at 5:00 p.m. ET

BURBANK, Calif.–(BUSINESS WIRE)–
Loop Media, Inc. (“Loop Media” or the “Company”) (NYSE American: LPTV), a leading multichannel streaming platform that provides curated music video and branded entertainment channels for businesses, will host a conference call on Tuesday, August 8, 2023 at 5:00 p.m. Eastern time to discuss its financial and operating results for the fiscal third quarter ended June 30, 2023.

Loop Media’s management will host the conference call, followed by a question and answer period.

Date: August 8, 2023

Time: 5:00 p.m. Eastern Time

Participant Registration Link

The conference call will also be available for replay on the investor relations section of the Company’s website at www.loop.tv/investors.

About Loop Media, Inc.

Loop Media, Inc. (“Loop Media”) (NYSE American: LPTV) is a leading CTV digital out of home (DOOH) TV and digital signage platform optimized for businesses, streaming more than 200 free music video, news, sports and entertainment channels through its Loop TV service. Loop Media is the leading company in the U.S. licensed to stream music videos to businesses through its proprietary Loop Player.

Loop Media’s digital video content reaches millions of viewers in DOOH locations including bars/restaurants, office buildings, retail businesses, college campuses, airports and on free ad-supported TV platforms and at local gas stations on GSTV terminals in the United States.

Loop is fueled by one of the largest and most important video libraries that includes music videos, movie trailers and live performances. Loop Media’s non-music channels cover a multitude of genres and moods and include movie trailers, sports highlights, lifestyle and travel videos, viral videos and more. Loop Media’s streaming services generate revenue from advertising and sponsorships and from subscriptions.

To learn more about Loop Media products and applications, please visit us online at Loop.tv

Follow us on social:

Instagram: @loopforbusiness

Twitter: @loopforbusiness

LinkedIn: https://www.linkedin.com/company/loopforbusiness/

Safe Harbor Statement and Disclaimer

This news release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, Loop Media’s expected 2023 results, ability to compete in the highly competitive markets in which it operates, statements regarding Loop Media’s ability to develop talent and attract future talent, the success of strategic actions Loop Media is taking, and the impact of strategic transactions. Forward-looking statements give our current expectations, opinion, belief or forecasts of future events and performance. A statement identified by the use of forward-looking words including “will,” “may,” “expects,” “projects,” “anticipates,” “plans,” “believes,” “estimate,” “should,” and certain of the other foregoing statements may be deemed forward-looking statements. Although Loop Media believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. Loop Media takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by Loop Media. Loop Media’s SEC filings are available at www.sec.gov.

Loop Media Investor Contact

James Cerna, Head of Capital Markets

[email protected]

Loop Media Press Contact

Jon Phillips

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Other Consumer Technology Entertainment Communications Audio/Video Other Entertainment Restaurant/Bar Social Media Consumer Retail

MEDIA:

Logo
Logo

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023


Increased focus on proprietary antibody platform and discontinuation of Vir’s 
innate immunity small molecule platform –


First participant to be dosed in Phase 1 trial of next-generation HIV vaccine,
 

VIR-1388, anticipated in Q3

– $1.9 billion in cash, cash equivalents and investments as of June 30, 2023 –

– Conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET, Aug. 3, 2023

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

“Our strategy is to prioritize our monoclonal antibody platform, which has already yielded two impactful medicines for patients and, along with our artificial intelligence-enabled capabilities, plan to apply it more broadly in infectious diseases and beyond,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “As we execute on this strategy, we look forward to our near-term catalysts, which include data readouts from our Phase 2 chronic hepatitis B and hepatitis delta programs in the fourth quarter. Our future prospects are rich with opportunity based on our deep pipeline and strong balance sheet.”


Pipeline Programs

Chronic Hepatitis B (CHB)

  • Multiple trials evaluating the potential for VIR-2218 and VIR-3434 to achieve a functional cure for CHB are on track with data expected in Q4 2023.
  • In June, the Company presented new data from its CHB portfolio at the EASL™ (European Association for the Study of the Liver) Congress.
  • In May, the Company announced the initiation of the Phase 2 PREVAIL platform trial and its THRIVE/STRIVE sub-protocols. The platform is evaluating combinations of VIR-2218, VIR-3434 and/or PEG-IFN-α in two CHB patient populations with the potential to evaluate other populations in the future. Initial data from this platform trial are expected in the first half of 2024.

Chronic Hepatitis Delta (CHD)

  • The Phase 2 SOLSTICE trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with CHD, the most aggressive form of viral hepatitis, remains on track with initial data expected in Q4 2023.
  • In June, the Company presented preclinical in vivo and in vitro data demonstrating the antiviral properties of VIR-2218 and VIR-3434 against hepatitis delta virus at the EASL Congress. These data further support the clinical development of these investigational medicines as a treatment for the chronic suppression of hepatitis delta virus.

Influenza

  • In July, Vir reported that the Phase 2 Prevention of Illness Due to Influenza A (PENINSULA) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.
  • The Company continues to analyze the data and plans to share additional findings once available.

Human Immunodeficiency Virus (HIV)

  • Vir expects the Phase 1 trial for VIR-1388, a novel T cell vaccine for the prevention of HIV, to begin dosing in Q3 2023. Vir’s T cell platform utilizes human cytomegalovirus (HCMV) as a vector, which has the potential to induce high frequencies of antigen-specific, tissue-localizing effector memory T cells. The trial will be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation, and will be conducted by the HIV Vaccine Trials Network. NIAID has provided funding throughout the product development lifecycle of VIR-1388.

COVID-19

  • Sotrovimab currently has emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy®️) for early treatment of COVID-19. It has been supplied to more than 40 countries and remains in use outside of the US.

Preclinical Pipeline Candidates

  • Vir is continuing to advance next-generation monoclonal antibodies (mAbs) based on its proprietary platform and enabled by AI and machine-learning capabilities to deliver high-quality solutions more efficiently. These include:
    • VIR-2981, an investigational neuraminidase-targeting mAb against both influenza A and B viruses.
    • VIR-8190, a mAb against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
    • VIR-7229, a next-generation COVID-19 mAb that has been shown in laboratory studies to have high potency against a broad spectrum of historical and currently circulating variants.
  • Additionally, the Company is advancing VIR-1949, a therapeutic T cell vaccine for control of precancerous lesions caused by human papillomavirus (HPV) based on Vir’s HCMV vector platform.


Corporate Update

  • In July, Vir made the decision to increase focus on its proprietary antibody platform and discontinue its innate immunity small molecule platform.
  • In June, Sasha Damouni Ellis joined Vir as Executive Vice President and Chief Corporate Affairs Officer. Previously, she was Senior Vice President, Corporate Affairs and Investor Relations of Marinus Pharmaceuticals.
  • In May, Jeff Calcagno, M.D., joined Vir as Executive Vice President and Chief Business Officer. He joined Vir from Johnson & Johnson (J&J), where he spent more than 12 years holding leadership roles of increasing responsibility within all three divisions of J&J Innovation (JJI), including as Global Transactions Lead for Infectious Diseases & Vaccines and as Head of JLABS Bay Area.


Second Quarter 2023 Financial Results

Cash, Cash Equivalents and Investments: As of June 30, 2023, the Company had approximately $1.9 billion in cash, cash equivalents and investments. In the second quarter of 2023, a payment of $273.6 million was made to GSK primarily for excess sotrovimab supply and manufacturing capacity that was reserved in 2022; a balance of $69.7 million remains, of which the Company anticipates making a payment of approximately $41.8 million to GSK in the third quarter of 2023.

Revenues: Total revenues for the quarter ended June 30, 2023, were $3.8 million compared to $(40.6) million for the same period in 2022.

Revenues were comprised of the following components:

(in millions) Three months ended

June 30
   
    2023    2022  % Change
Collaboration revenue   $(13.8 )   $(54.9 ) (74.9 %)
Contract revenue   1.1     12.3   (91.1 %)
Grant revenue   16.5     2.1   >100 %
Total revenues   $3.8     $(40.6 ) >100


%

Note: Numbers may not add due to rounding.
 
  • Collaboration revenue: The year-over-year change in collaboration revenue was primarily driven by a $397.4 million charge for a profit-share constraint recorded in the second quarter of 2022 which more than offset the $342.5 million profit-sharing amount recorded in the same quarter. The constraint represents an estimate for excess sotrovimab supply and manufacturing capacity and reduces the profit-sharing amount. In the second quarter of 2023, collaboration revenue was $(13.8) million primarily due to sotrovimab sales that were more than offset by manufacturing costs and expenses to support activities where sotrovimab has marketing authorization. These activities are led by the Company’s collaboration partner GSK.
  • Contract revenue: The decrease in contract revenue was primarily driven by a $7.0 million upfront payment related to a license granted to GSK in the second quarter of 2022.
  • Grant revenue: The increase in grant revenue was primarily driven by $11.8 million related to the Company’s grant with Biomedical Advanced Research and Development Authority (BARDA) supporting the Company’s Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness in the second quarter of 2023.

Cost of Revenue: Cost of revenue for the second quarter of 2023 was not material compared to $27.9 million for the same period in 2022. The decrease was due to lower third-party royalties owed based on the sales of sotrovimab.

Research and Development Expenses (R&D): R&D expenses for the second quarter of 2023 were $171.9 million, which included $17.1 million of non-cash stock-based compensation expense, compared to $115.1 million for the same period in 2022, which included $14.1 million of non-cash stock-based compensation expense. The increase was primarily driven by higher investments to support the advancement of our clinical programs and, in particular, VIR-2482.

Selling, General and Administrative Expenses (SG&A): SG&A expenses for the second quarter of 2023 were $47.1 million, which included $13.5 million of non-cash stock-based compensation expense, compared to $41.6 million for the same period in 2022, which included $13.0 million of non-cash stock-based compensation expense. The increase was primarily due to higher personnel-related costs to support the growth of the Company.

Other Income (Expense): Other income for the second quarter of 2023 was $17.6 million compared to other expense of $(8.5) million for the same period in 2022. The increase was primarily due to higher interest income related to higher interest rates along with an overall higher investment balance.

Benefit from Income Taxes: Benefit from income taxes for the second quarter of 2023 was $2.8 million compared to $157.2 million benefit from income taxes for the same period in 2022. The decrease was primarily due to the Company’s inability to realize tax benefit associated with the net loss for the three months ended June 30, 2023.

Net Loss: Net loss attributable to Vir for the second quarter of 2023 was $194.8 million, or $1.45 per share, basic and diluted, compared to a net loss of $76.5 million, or $0.58 per share, basic and diluted, for the same period in 2022.


Conference Call


Vir will host a conference call to discuss the Q2 results at 1:30 p.m. PT / 4:30 p.m. ET today. A live webcast will be available on https://investors.vir.bio/ and will be archived on www.vir.bio for 30 days.

About VIR-2218

VIR-2218 is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an effective immune response and have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially could result in an increased therapeutic index. VIR-2218 is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

About VIR-3434

VIR-3434 is an investigational subcutaneously administered antibody designed to block entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to potentially function as a T cell vaccine against hepatitis B virus and hepatitis delta virus, as well as to have an extended half-life. VIR-3434 was identified using Vir’s proprietary mAb discovery platform.

About VIR-2482

VIR-2482 is an investigational hemagglutinin targeting, intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 flu pandemic. VIR-2482 is designed as a prophylactic for influenza A. VIR-2482, which incorporates Xencor’s Xtend™ technology, also has been half-life engineered so that a single dose has the potential to last the entire flu season. VIR-2482 was identified using Vir’s proprietary mAb discovery platform. Under the collaboration agreement signed with GSK in 2021, GSK has an exclusive option to lead post-Phase 2 development and commercialization of VIR-2482.

The PENINSULA trial has been supported in whole or in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081.

About VIR-2981

VIR-2981 is an investigational neuraminidase-targeting monoclonal antibody against influenza viruses. It targets a region of the neuraminidase protein that is highly conserved across influenza A and B strains and is designed to inhibit the influenza neuraminidase, a key viral protein that facilitates release of new viruses in infected individuals. Preclinical data demonstrate the antibody’s breadth and potency against all major strains of seasonal and pandemic influenza viruses and support the potential of this antibody in the prevention of influenza illness. Vir-2981 was identified using Vir’s proprietary mAb discovery platform.

About VIR-1388

VIR-1388 is an investigational subcutaneously administered HIV T cell vaccine based on HCMV that has been designed to elicit abundant T cells that recognize HIV proteins in a way that differs from prior investigational HIV vaccines. VIR-1388 uses applied learnings from VIR-1111, Vir’s initial investigational proof-of-concept HIV T cell vaccine, with the goal of creating a safe and effective HIV vaccine. VIR-1388 was identified using Vir’s proprietary mAb discovery platform.

About Sotrovimab
Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody that was developed in collaboration with GSK. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS). Sotrovimab, which incorporates Xencor, Inc.’s Xtend™️ technology, has been designed to achieve high concentration in the lungs to achieve optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. Sotrovimab was identified using Vir’s proprietary mAb discovery platform. Sotrovimab is currently not authorized in the US.

About VIR-7229

VIR-7229 is a preclinical monoclonal antibody that neutralizes all historical and currently circulating COVID-19 variants with high potency in vitro. Vir-7229 incorporates Xencor, Inc.’s Xtend™️ technology. VIR-7229 was identified using Vir’s proprietary mAb discovery platform.

About VIR-8190

VIR-8190 is a dual specificity monoclonal antibody that has the ability to potently neutralize both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) strains. RSV and HMPV are recognized as significant causes of lower respiratory tract disease in high-risk populations, including infants and immunocompromised individuals. VIR-8190 was identified using Vir’s proprietary mAb discovery platform.

About VIR-1949

VIR-1949 is a preclinical therapeutic vaccine designed to treat HPV-related high-grade squamous epithelial pre-cancer lesions (HSIL) and cancers. This vaccine uses HCMV as the vaccine vector. Based on preclinical data, HCMV vectors have the potential to induce high frequencies of antigen-specific, tissue-localizing effector memory T cells.

About Vir Biotechnology

Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious conditions. Vir has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis B and hepatitis delta viruses, influenza A and B, human immunodeficiency virus and COVID-19. Vir has several preclinical candidates in its pipeline. Vir routinely posts information that may be important to investors on its website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans; Vir’s cash balance; Vir’s future financial and operating results and its expectations related thereto; potential of, and expectations for, Vir’s pipeline; Vir’s clinical development programs, clinical trials, including the enrollment of Vir’s clinical trials, and the expected timing of data readouts and presentations; the potential benefits, safety, and efficacy of Vir’s investigational therapies; and risks and uncertainties associated with drug development and commercialization. Many important factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the timing and outcome of Vir’s planned interactions with regulatory authorities; difficulties in obtaining regulatory approval; uncertainty as to whether the anticipated benefits of Vir’s collaborations with other companies can be achieved; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; clinical site activation rates or clinical trial enrollment rates that are lower than expected; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials, geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the US Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

VIR BIOTECHNOLOGY, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
(unaudited)
 
  June 30,

2023
  December 31,

2022
ASSETS      
CURRENT ASSETS:      
Cash and cash equivalents $ 666,949     $ 848,631  
Short-term investments   1,166,953       1,521,517  
Restricted cash and cash equivalents, current   13,163       12,681  
Equity investments   13,531       31,892  
Prepaid expenses and other current assets   85,736       104,356  
Total current assets   1,946,332       2,519,077  
Intangible assets, net   25,590       32,755  
Goodwill   16,937       16,937  
Property and equipment, net   104,126       105,609  
Operating right-of-use assets   74,934       82,557  
Restricted cash and cash equivalents, noncurrent   6,744       6,656  
Long-term investments   52,358       23,927  
Other assets   16,853       14,570  
TOTAL ASSETS $ 2,243,874     $ 2,802,088  
LIABILITIES AND STOCKHOLDERS’ EQUITY      
CURRENT LIABILITIES:      
Accounts payable $ 12,362     $ 6,422  
Accrued and other liabilities   197,580       489,090  
Deferred revenue, current portion   15,681       15,517  
Total current liabilities   225,623       511,029  
Deferred revenue, noncurrent   53,207       53,207  
Operating lease liabilities, noncurrent   117,815       123,837  
Contingent consideration, noncurrent   24,927       24,937  
Other long-term liabilities   12,094       11,115  
TOTAL LIABILITIES   433,666       724,125  
Commitments and contingencies (Note 7)      
STOCKHOLDERS’ EQUITY:      
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022; no shares issued and outstanding as of June 30, 2023 and December 31, 2022          
Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 134,230,494 and 133,236,687 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively   13       13  
Additional paid-in capital   1,771,536       1,709,835  
Accumulated other comprehensive loss   (2,903 )     (9,122 )
Retained earnings   41,562       377,237  
TOTAL STOCKHOLDERS’ EQUITY   1,810,208       2,077,963  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 2,243,874     $ 2,802,088  

VIR BIOTECHNOLOGY, INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
 
 
  Three Months Ended
June 30,
  Six Months Ended
June 30,
    2023       2022       2023       2022  
Revenues:              
Collaboration revenue $ (13,779 )   $ (54,941 )   $ 32,795     $ 1,174,715  
Contract revenue   1,057       12,254       1,195       12,536  
Grant revenue   16,519       2,058       32,764       4,579  
Total revenues   3,797       (40,629 )     66,754       1,191,830  
Operating expenses:              
Cost of revenue   22       27,921       1,929       118,070  
Research and development   171,860       115,082       329,503       205,309  
Selling, general and administrative   47,101       41,590       93,879       79,845  
Total operating expenses   218,983       184,593       425,311       403,224  
(Loss) income from operations   (215,186 )     (225,222 )     (358,557 )     788,606  
Other income (expense):              
Change in fair value of equity investments   (5,086 )     (11,390 )     (18,189 )     (106,429 )
Interest income   23,016       2,200       44,323       2,588  
Other (expense) income, net   (367 )     691       (8,388 )     3,421  
Total other income (expense)   17,563       (8,499 )     17,746       (100,420 )
(Loss) income before benefit from (provision for) income taxes   (197,623 )     (233,721 )     (340,811 )     688,186  
Benefit from (provision for) income taxes   2,848       157,228       5,080       (246,058 )
Net (loss) income $ (194,775 )   $ (76,493 )   $ (335,731 )   $ 442,128  
Net loss attributable to noncontrolling interest $     $     $ (56 )   $  
Net (loss) income attributable to Vir $ (194,775 )   $ (76,493 )   $ (335,675 )   $ 442,128  
Net (loss) income per share attributable to Vir, basic $ (1.45 )   $ (0.58 )   $ (2.51 )   $ 3.34  
Net (loss) income per share attributable to Vir, diluted $ (1.45 )   $ (0.58 )   $ (2.51 )   $ 3.28  
Weighted-average shares outstanding, basic   134,059,079       132,450,018       133,807,357       132,326,244  
Weighted-average shares outstanding, diluted   134,059,079       132,450,018       133,807,357       134,643,840  
                               



Contacts:

Media
Carly Scaduto
Senior Director, Media Relations
[email protected]
+1-314-368-5189

Investors
Sasha Damouni Ellis
Executive Vice President, Chief Corporate Affairs Officer
[email protected]

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291(KRASG12C) and RMC-9805 (KRASG12D) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-0708 (KRASQ61H) which is currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).



Investors & Media Contact:
Erin Graves
650-779-0136
[email protected]

eMagin to Announce Second-Quarter 2023 Results on August 10, 2023

HOPEWELL JUNCTION, N.Y., Aug. 03, 2023 (GLOBE NEWSWIRE) — eMagin Corporation or the “Company,” (NYSE American: EMAN), a leader in the development, design, and manufacture of high-resolution micro-OLED displays for virtual and augmented reality solutions, today announced it will release its second-quarter results on Thursday, August 10, 2023.

Earnings Conference Call and Webcast
Management will host a conference call and simultaneous webcast at 9:00 a.m. ET on August 10, 2023, to discuss its quarterly results. The live, listen-only webcast will be accessible on the Company’s Investor Relations website via https://www.emagin.com/investors/event-webcast. A replay of the event will be available shortly after the live event. To join the conference call participants will need to register with this link. Participants will receive an individualized dial-in number and PIN after registering for the call.

About eMagin Corporation

eMagin is the leader in OLED microdisplay technology, enabling the visualization of digital information and imagery for world-class customers in the military, consumer, medical and industrial markets. The Company invents, engineers and manufactures display technologies of the future and is the only manufacturer of OLED displays in the United States. eMagin’s Direct Patterning Technology (dPd™) will transform the way the world consumes information. Since 2001, eMagin’s microdisplays have been used in AR/VR, aircraft helmets, heads-up display systems, thermal scopes, night vision goggles, future weapon systems and a variety of other applications. For more information, please visit www.emagin.com.

Contact:

eMagin Corporation

Mark Koch, Chief Financial Officer

845-838-7900
[email protected]

Sharon Merrill Advisors, Inc.

Nicholas Manganaro

617-542-5300
[email protected]



CNB Financial Corporation Announces Quarterly Dividend for Series A Preferred Stock and Related Depositary Shares Distribution

CLEARFIELD, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) — The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) (the “Corporation”) has announced the declaration of a quarterly cash dividend of $0.4453125 per depositary share, resulting from the Corporation’s declaration of a quarterly cash dividend of $17.8125 per share on its Series A Preferred Stock. The dividend is payable on September 1, 2023, to holders of record as of August 18, 2023.

CNB Financial Corporation is a financial holding company with consolidated assets of approximately $5.7 billion. CNB Financial Corporation conducts business primarily through its principal subsidiary, CNB Bank. CNB Bank is a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. CNB Bank operations include a private banking division, two loan production offices, one drive-up office, one mobile office and 51 full-service offices in Pennsylvania, Ohio, New York and Virginia. CNB Bank’s divisions include ERIEBANK, based in Erie, Pennsylvania, with offices in Northwest Pennsylvania and Northeast Ohio; FCBank, based in Worthington, Ohio, with offices in Central Ohio; BankOnBuffalo, based in Buffalo, New York, with offices in Western New York; Ridge View Bank, with offices in the Southwest Virginia region; and Impressia Bank which operates in CNB Bank’s primary market areas. CNB Bank is headquartered in Clearfield, Pennsylvania, with offices in Central and North Central Pennsylvania. Additional information about CNB Financial Corporation may be found at www.CNBBank.bank.



Contact: Tito L. Lima
Treasurer  
(814) 765-9621

AdTheorent Holding Company, Inc. Reports Second Quarter 2023 Results and Reaffirms Full-Year 2023 Outlook

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — AdTheorent Holding Company, Inc. (Nasdaq: ADTH) (“AdTheorent” or “the Company”), a machine learning pioneer and industry leader using privacy-forward solutions to deliver measurable value for programmatic advertisers, today announced its second quarter 2023 financial results.

“As we exit the second quarter, we look confidently towards a second half return to meaningful revenue growth, reflected in strong quarter-to-date bookings, growing late-stage pipeline, and impressive results across each of our strategic investments including self-service (or Direct Access), CTV, AdTheorent predictive (ID-free) audience products, and AdTheorent Health,” said James Lawson, CEO of AdTheorent. “This confidence is underpinned by our decade-plus leadership in AI/ML and the near-term launch of our first-of-its-kind self-service Health DSP, an innovation that’s already eliciting an overwhelmingly positive response in customer previews.”


Second Quarter 2023 Financial Overview:

  • Revenue was $37.6 million, a 11.5% decrease compared to $42.5 million in the second quarter of 2022.
  • Gross profit was $16.9 million, down 22.1%, from $21.6 million in the second quarter of 2022. Gross Profit Margin was 44.8%, compared to 50.9% in the second quarter of 2022.
  • Adjusted Gross Profit* decreased $4.3 million, or 15.2%, to $24.0 million compared to the second quarter of 2022. Adjusted Gross Profit Margin was 64.0% compared to 66.7% in the second quarter of 2022.
  • Net income decreased $49.7 million, to $8.1 million, from $57.8 million in the second quarter of 2022. In the second quarter of 2022, the Company recognized a total of $55.9 million of mark to market gains related to fair value of the Seller’s Earn-Out and Warrants liabilities compared to gains of $0.7 million in the second quarter of 2023.
  • Adjusted EBITDA* decreased $4.0 million to $3.3 million compared to second quarter 2022. Adjusted EBITDA as a percentage of Adjusted Gross Profit of 13.8% represented a decrease from 25.8% in the second quarter of 2022.


Second Quarter and Recent Business and Operating Highlights:

  • AdTheorent’s self-service platform revenue increased 75% sequentially in the second quarter, an acceleration of the 19% sequential revenue growth in the first quarter.
  • AdTheorent Health experienced continued momentum with a 36% year-over-year increase in advertiser count in the second quarter, and sustained adoption of our algorithm-based and ID-independent AdTheorent Health Audiences, built by HABi™, with 19 active campaigns in the second quarter and 25 campaigns booked for the third quarter to date.
  • AdTheorent’s algorithm-based and ID-independent predictive audiences for non-health advertisers, built by ABi™, continued to yield strong customer adoption with 50 active campaigns in the second quarter and 37 campaigns booked for the third quarter to date.
  • AdTheorent’s algorithm-based predictive audience products earned Neutronian’s NQI Certification for Data Quality, Privacy and Transparency, and AdTheorent earned the top ranking among pure play DSPs in Neutronian’s Q2 Data Privacy Scores report, further strengthening the Company’s position as a machine-learning focused industry leader.
  • In July, AdTheorent was awarded Frost & Sullivan’s 2023 North American Product Leadership Award for its groundbreaking algorithm-based and ID-independent audience targeting solutions.
  • The launch of AdTheorent’s highly-specialized AdTheorent Health self-service DSP remains on track for the third quarter of 2023.

*We prepare our consolidated financial statements in accordance with the U.S. generally accepted accounting principles (“GAAP”).
Adjusted Gross Profit and Adjusted EBITDA are non-GAAP financial measures. See the supplementary schedules in this press release for a discussion of how we define and calculate these measures and a reconciliation thereof to the most directly comparable GAAP measures.


Third Quarter and Full-Year 2023 Financial Outlook:

The Company’s growth may continue to be impacted in 2023 by macroeconomic factors beyond its control, such as inflationary pressures and recessionary fears. Based on the current business environment, recent performance and the current trends in the marketplace and subject to the risks and uncertainties inherent in forward-looking statements, the Company’s outlook for the third quarter and full-year 2023 includes the following:

Third quarter 2023:

  • Revenue in the range of $39.0 million to $42.0 million.
  • Adjusted Gross Profit* of approximately 64% of revenue.
  • Adjusted EBITDA* in the range of $3.0 million to $4.5 million.

Full-year ending December 31, 2023:

  • Revenue growth compared to 2022.
  • Adjusted Gross Profit* between 64% to 65% of revenue.
  • Adjusted EBITDA* margin of between 16% and 19%.

Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for the Company to provide guidance on net income or to reconcile its Adjusted EBITDA guidance to net income without unreasonable efforts. Similarly, although the Company provides guidance for Adjusted Gross Profit, it is not able to provide guidance for Gross Profit, the most directly comparable GAAP measure. Certain elements of the composition of Gross Profit, including equity-based compensation, are not predictable, making it impractical for the Company to provide guidance on Gross Profit or to reconcile its Adjusted Gross Profit guidance to Gross Profit without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income and Gross Profit, which could be material to future results.


About AdTheorent:

AdTheorent uses advanced machine learning technology and privacy-forward solutions to deliver impactful advertising campaigns for marketers. AdTheorent’s advanced machine learning-powered media buying platform powers its predictive targeting, predictive audiences, geo-intelligence, audience extension solutions and in-house creative capability, Studio A\T. Leveraging only non-sensitive data and focused on the predictive value of machine learning models, AdTheorent’s product suite and flexible transaction models allow advertisers to identify the most qualified potential consumers coupled with the optimal creative experience to deliver superior results, measured by each advertiser’s real-world business goals. AdTheorent is headquartered in New York, with fourteen locations across the United States and Canada.

AdTheorent is consistently recognized with numerous technology, product, growth and workplace awards. AdTheorent was named an AdExchanger 2022 Top 50 Programmatic Power Player and was honored with an AI Breakthrough Award and “Most Innovative Product” (B.I.G. Innovation Awards) for six consecutive years. Additionally, AdTheorent is the only seven-time recipient of Frost & Sullivan’s “Digital Advertising Leadership Award.” In September 2022, evidencing its continued prioritization of its team, AdTheorent was named a Crain’s Top 100 Best Place to Work in NYC for the ninth consecutive year. AdTheorent ranked fifth in the Large Employer Category and 17th Overall in 2022. For more information, visit adtheorent.com.


Conference Call and Webcast Details:

AdTheorent will host a conference call and webcast at 4:30 p.m. ET today, August 3, 2023, to discuss its second quarter 2023 financial results and business highlights. The conference call can be accessed by dialing (800) 715-9871 from the United States and Canada or (646) 307-1963 International with Conference ID 1908045. The live webcast of the conference call and other materials related to AdTheorent’s financial performance can be accessed from AdTheorent’s investor relations website at investors.adtheorent.com.

Following the completion of the call until 11:59 p.m. ET on Thursday, August 10, 2023, a telephone replay will be available by dialing (800) 770-2030 from the United States and Canada, or (609) 800-9909 International with Conference ID 1908045. A webcast replay will also be available at investors.adtheorent.com for 12 months.


Forward-Looking Statements:

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as “believe,” “anticipate,” “expect,” “estimate,” “intend,” “project,” “plan,” or words or phrases with similar meaning. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements contained in this press release relate to, among other things, the Company’s projected financial performance and operating results, including projected revenue, Adjusted Gross Profit and Adjusted EBITDA, as well as statements regarding inflationary pressures and recessionary fears.

Forward-looking statements are based on current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, the market for programmatic advertising developing slower or differently than the Company’s expectations, the demands and expectations of clients and the ability to attract and retain clients and other economic, competitive, governmental and technological factors outside of the Company’s control, that may cause the Company’s business, strategy or actual results to differ materially from the forward-looking statements. The Company does not intend and undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable law. Investors are referred to AdTheorent’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and any subsequent filings on Forms 10-Q or 8-K, for additional information regarding the risks and uncertainties that may cause actual results to differ materially from those expressed in any forward-looking statement.

Investor Contact:

April Scee, ICR
[email protected]
(646) 277-1219

Press Contact:

Melanie Berger, AdTheorent
[email protected]
(850) 567-0082

ADTHEORENT HOLDING COMPANY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited; in thousands)

  June 30,     December 31,  
  2023     2022  

ASSETS
         
Current assets          
Cash and cash equivalents $ 73,061     $ 72,579  
Accounts receivable, net   42,362       56,027  
Income tax recoverable   177       145  
Prepaid expenses   10,026       1,466  
Total current assets   125,626       130,217  
Property and equipment, net   494       520  
Operating lease right of use assets   5,234       5,732  
Investment in SymetryML Holdings   631       789  
Customer relationships, net   2,237       4,475  
Other intangible assets, net   7,412       6,708  
Goodwill   34,842       34,842  
Deferred income taxes, net   10,037       6,962  
Other assets   345       359  
Total assets $ 186,858     $ 190,604  
           

LIABILITIES AND STOCKHOLDERS’ EQUITY
         
Current liabilities          
Accounts payable $ 8,759     $ 9,479  
Accrued compensation   3,117       8,939  
Accrued expenses   4,097       6,224  
Operating lease liabilities, current   1,268       1,265  
Total current liabilities   17,241       25,907  
Warrants   2,152       2,298  
Seller’s Earn-Out   248       773  
Operating lease liabilities, non-current   5,564       6,201  
Total liabilities   25,205       35,179  
Stockholders’ equity          
Preferred Stock          
Common Stock   9       9  
Additional paid-in capital   86,935       83,566  
Retained earnings   74,709       71,850  
Total stockholders’ equity   161,653       155,425  
Total liabilities and stockholders’ equity $ 186,858     $ 190,604  

ADTHEORENT HOLDING COMPANY, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited; in thousands, except share and per share data)

  Three Months Ended
June 30,
    Six Months Ended

June 30,
 
  2023     2022     2023     2022  
Revenue $ 37,587     $ 42,476     $ 70,261     $ 76,717  
Operating expenses:                      
Platform operations   20,735       20,854       39,122       38,626  
Sales and marketing   10,624       11,083       20,931       21,413  
Technology and development   3,368       4,153       6,659       8,438  
General and administrative   3,589       5,103       7,525       10,704  
Total operating expenses   38,316       41,193       74,237       79,181  
(Loss) income from operations   (729 )     1,283       (3,976 )     (2,464 )
Interest income (expense), net   424       (47 )     1,043       (156 )
Gain on change in fair value of Seller’s Earn-Out   292       37,419       525       12,763  
Gain on change in fair value of warrants   415       18,523       146       2,587  
Gain on deconsolidation of SymetryML                     1,939  
Loss on change in fair value of SAFE Notes                     (788 )
Gain (loss) on fair value of investment in SymetryML Holdings   10       (10 )     (158 )     (10 )
Other income (expense), net   4       (1 )     (37 )     (19 )
Total other income, net   1,145       55,884       1,519       16,316  
Net income (loss) before income taxes   416       57,167       (2,457 )     13,852  
Benefit for income taxes   7,666       610       5,316       1,635  
Net income $ 8,082     $ 57,777     $ 2,859     $ 15,487  
Less: Net loss attributable to noncontrolling interest                     550  
Net income attributable to AdTheorent Holding Company, Inc. $ 8,082     $ 57,777     $ 2,859     $ 16,037  
Earnings per share:                      
Basic $ 0.09     $ 0.67     $ 0.03     $ 0.19  
Diluted $ 0.09     $ 0.62     $ 0.03     $ 0.17  
Weighted-average common shares outstanding:                      
Basic   87,874,081       85,766,302       87,713,571       85,775,210  
Diluted   92,787,955       93,402,650       92,407,260       93,283,519  

ADTHEORENT HOLDING COMPANY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited; in thousands)

  Six Months Ended June 30,  
  2023     2022  
Cash flows from operating activities          
Net income $ 2,859     $ 15,487  
Adjustments to reconcile net income to net cash provided by operating activities:          
Provision for credit losses         172  
Amortization expense   4,204       3,950  
Depreciation expense   98       92  
Amortization of debt issuance costs   28       28  
Gain on change in fair value of Seller’s Earn-Out   (525 )     (12,763 )
Gain on change in fair value of warrants   (146 )     (2,587 )
Gain on deconsolidation of SymetryML         (1,939 )
Loss on change in fair value of SAFE Notes         788  
Loss on fair value of investment in SymetryML Holdings   158       10  
Deferred tax benefit   (3,075 )     (3,236 )
Equity-based compensation   3,340       5,844  
Seller’s Earn-Out equity-based compensation         991  
Changes in operating assets and liabilities:          
Accounts receivable   13,665       11,675  
Income taxes recoverable   (32 )     (4 )
Prepaid expenses and other assets   (8,076 )     (3,626 )
Accounts payable   (779 )     (2,440 )
Accrued compensation, accrued expenses, and other liabilities   (8,583 )     (9,153 )
Net cash provided by operating activities   3,136       3,289  
Cash flows from investing activities          
Capitalized software development costs   (2,470 )     (1,240 )
Purchase of property and equipment   (69 )     (211 )
Decrease in cash from deconsolidation of SymetryML         (69 )
Net cash used in investing activities   (2,539 )     (1,520 )
Cash flows from financing activities          
Cash received for exercised options   150       183  
Payment of revolver borrowings         (39,017 )
Proceeds from SAFE Notes         200  
Proceeds from SymetryML preferred stock issuance         400  
Taxes paid related to net settlement of restricted stock awards   (437 )      
Proceeds from employee stock purchase plan   172        
Net cash used in financing activities   (115 )     (38,234 )
Net increase (decrease) in cash and cash equivalents   482       (36,465 )
Cash and cash equivalents at beginning of period   72,579       100,093  
Cash and cash equivalents at end of period $ 73,061     $ 63,628  
        
   

Non-GAAP Financial Measures

The Company uses financial measures that are not calculated in accordance with GAAP including Adjusted EBITDA and Adjusted Gross Profit. The Company’s management believes that this information can assist investors in evaluating the Company’s operational trends, financial performance, and cash generating capacity and make strategic decisions. Management believes these non-GAAP measures allow investors to evaluate the Company’s financial performance using some of the same measures as management.

Because of the limitations associated with these non-GAAP financial measures, “Adjusted Gross Profit,” “EBITDA,” “Adjusted EBITDA,” “Adjusted Gross Profit as a percentage of Revenue” and “Adjusted EBITDA as a percent of Adjusted Gross Profit” should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. The Company compensates for these limitations by relying primarily on its GAAP results and using non-GAAP measures on a supplemental basis. You should review the reconciliation of the non-GAAP financial measures below and not rely on any single financial measure to evaluate AdTheorent’s business.

The tables below show the Company’s non-GAAP financial metrics reconciled to the comparable GAAP financial metrics included in this release.

Adjusted Gross Profit

Adjusted Gross Profit is a non-GAAP profitability measure. Adjusted Gross Profit is a non-GAAP financial measure of campaign profitability, monitored by management and the board, used to evaluate the Company’s operating performance and trends, develop short- and long-term operational plans, and make strategic decisions regarding the allocation of capital. The Company believes this measure provides a useful period-to-period comparison of campaign profitability and is useful information to investors and the market in understanding and evaluating its operating results in the same manner as its management and board. Gross profit is the most comparable GAAP measurement, which is calculated as revenue less platform operations costs. In calculating Adjusted Gross Profit, the Company adds back other platform operations costs, which consist of amortization expense related to capitalized software, depreciation expense, allocated costs of personnel which set up and monitor campaign performance, and platform hosting, license, and maintenance costs, to gross profit.

The following table sets forth a reconciliation of revenue to Adjusted Gross Profit for the periods presented:

  Three Months Ended
June 30,
  Six Months Ended

June 30,
  2023   2022   2023   2022
  (In thousands)
Revenue $ 37,587   $ 42,476   $ 70,261   $ 76,717
Less: Platform operations   20,735     20,854     39,122     38,626
Gross Profit   16,852     21,622     31,139     38,091
Add back: Other platform operations   7,190     6,724     13,800     13,240
Adjusted Gross Profit $ 24,042   $ 28,346   $ 44,939   $ 51,331
                       

EBITDA and Adjusted EBITDA

EBITDA is a non-GAAP financial measure defined by us as net income, before interest (income) expense, net; depreciation, amortization; and income tax benefit. Adjusted EBITDA is defined as EBITDA before equity-based compensation expense, transaction costs, non-core operations and other non-recurring items. Net income is the most comparable GAAP measurement.

Collectively these non-GAAP financial measures are key profitability measures used by the Company’s management and board to understand and evaluate its operating performance and trends, develop short-and long-term operational plans and make strategic decisions regarding the allocation of capital. The Company believes that these measures can provide useful period-to-period comparisons of campaign profitability. Accordingly, the Company believes that these measures provide useful information to investors and the market in understanding and evaluating its operating results in the same manner as its management and board.

The following table sets forth a reconciliation of net income to Adjusted EBITDA for the periods presented:

  Three Months Ended
June 30,
    Six Months Ended

June 30,
 
  2023


    2022     2023     2022  
  (In thousands)  
Net income $ 8,082     $ 57,777     $ 2,859     $ 15,487  
Interest (income) expense, net   (424 )     47       (1,043 )     156  
Tax benefit   (7,666 )     (610 )     (5,316 )     (1,635 )
Depreciation and amortization   2,194       1,954       4,302       4,042  
EBITDA $ 2,186     $ 59,168     $ 802     $ 18,050  
Equity-based compensation   1,860       3,856       3,340       5,844  
Seller’s Earn-Out equity-based compensation         499             991  
Transaction costs (1)         (271 )     166       (131 )
Gain on change in fair value of Seller’s Earn-Out (2)   (292 )     (37,419 )     (525 )     (12,763 )
Gain on change in fair value of warrants (3)   (415 )     (18,523 )     (146 )     (2,587 )
Gain on deconsolidation of SymetryML (4)                     (1,939 )
Loss on change in fair value of SAFE Notes (5)                     788  
(Gain) loss on fair value of investment in SymetryML Holdings   (10 )     10       158       10  
Non-core operations (6)                     351  
Adjusted EBITDA $ 3,329     $ 7,320     $ 3,795     $ 8,614  

(1) Includes professional fees directly related to the SPAC merger with MCAP Acquisition Corporation (the “Business Combination”) on December 22, 2021.
(2) In connection with the Business Combination, a Seller’s Earn-Out liability was recorded. The gain represents the decrease in fair value of the Seller’s Earn-Out in the three and six months ended June 30, 2023 and 2022.
(3) In connection with the Business Combination, a liability for warrants was recorded. The gain represents the decrease in fair value of the warrants in the three and six months ended June 30, 2023 and 2022.
(4) On March 31, 2022, the Company deconsolidated SymetryML which resulted in a gain. Refer to Note 16 — SymetryML and SymetryML Holdings of the Company’s Condensed Consolidated Financial Statements, included in its Form 10-Q as of June 30, 2023, filed today, for more information.
(5) On March 31, 2022, the SAFE Notes (defined below) were valued which resulted in a loss. Refer to Note 16 — SymetryML and SymetryML Holdings of the Company’s Condensed Consolidated Financial Statements, included in its Form 10-Q as of June 30, 2023, filed today, for more information.
(6) Effective as of March 1, 2020, the Company effectuated a contribution of its SymetryML department into a new subsidiary, SymetryML, Inc. The Company periodically raised capital to fund Symetry operations, by entering into Simple Agreement for Future Equity Notes (“SAFE Notes”) with several parties. The Company viewed SymetryML operations as non-core, and did not fund future operational expenses incurred in excess of SAFE Note funding secured. Effective March 31, 2022, the Company deconsolidated SymetryML. Refer to Note 16 — SymetryML and SymetryML Holdings of the Company’s Condensed Consolidated Financial Statements, included in its Form 10-Q as of June 30, 2023, filed today, for more information.


The following table presents Adjusted EBITDA as a Percentage of Adjusted Gross Profit and Adjusted Gross Profit as a Percentage of Revenue:

  Three Months Ended June 30,     Six Months Ended June 30,  
  2023     2022     2023     2022  
  (In thousands, except percentages)  
Gross Profit $ 16,852     $ 21,622     $ 31,139     $ 38,091  
Net income $ 8,082     $ 57,777     $ 2,859     $ 15,487  
Net income as a percentage of Gross Profit   48.0 %     267.2 %     9.2 %     40.7 %
Adjusted Gross Profit $ 24,042     $ 28,346     $ 44,939     $ 51,331  
Adjusted EBITDA $ 3,329     $ 7,320     $ 3,795     $ 8,614  
Adjusted EBITDA as a percentage of Adjusted Gross Profit   13.8 %     25.8 %     8.4 %     16.8 %
Gross Profit $ 16,852     $ 21,622     $ 31,139     $ 38,091  
Revenue $ 37,587     $ 42,476     $ 70,261     $ 76,717  
Gross Profit as a percentage of Revenue   44.8 %     50.9 %     44.3 %     49.7 %
Revenue $ 37,587     $ 42,476     $ 70,261     $ 76,717  
Adjusted Gross Profit $ 24,042     $ 28,346     $ 44,939     $ 51,331  
Adjusted Gross Profit as a percentage of Revenue   64.0 %     66.7 %     64.0 %     66.9 %



Sensus Healthcare Reports Second Quarter 2023 Financial Results


  • Revenues increased 33% and system shipments increased 30%, both compared with the first quarter of 2023

  • Achieved a milestone with the installation of 700 systems for a total of 708

  • Expects to ship at least 60 SRT units during 2023 and to return to profitability in the second half of the year

Conference call begins at 4:30 p.m. Eastern time today

BOCA RATON, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and six months ended June 30, 2023.

Highlights from the second quarter of 2023 and recent weeks include the following:

  • Achieved revenues of $4.5 million, an increase of 33% from $3.4 million for the first quarter of 2023 and a decrease from $12.1 million in the prior-year quarter reflecting lower SRT unit sales
  • Shipped 13 SRT systems including four outside the U.S. and six SRT-100 Vision™ systems, an increase from 10 systems shipped during the first quarter of 2023 and a decrease from 33 systems shipped in the prior-year quarter
  • Surpassed 700 total systems, with 708 sold worldwide.
  • Narrowed the net loss to $0.4 million, or $0.02 per share, from a net loss of $1.9 million, or $0.12 per share, for the first quarter of 2023 and versus net income of $3.5 million, or $0.21 per diluted share, for the prior-year quarter
  • Ended the quarter with $20.1 million in cash and cash equivalents, and no debt
  • Sold the first SRT System in Ireland, to Dublin’s Beacon Hospital
  • Engaged MIS Healthcare to distribute SRT systems in the United Kingdom and Ireland
  • Anticipates profitability for the second half of the year based on a growing number of prospects

Management Commentary

“Many of our customers depend on elective aesthetic procedures as a meaningful source of practice revenue and profit, and we are hearing encouraging feedback that patient volumes and procedure mix are improving. Our second quarter financial results reflect that dynamic and strengthened considerably compared with the first quarter,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “We expect to return to profitability in the second half of the year as these trends continue. In preparation, we continued to build inventory and prepay for components.

“International expansion is an important strategic goal and we were delighted to enter into a new partnership with MIS Healthcare to distribute SRT systems in the United Kingdom and British Isles. Prior to that engagement our internal sales staff had been working for several months with Beacon Hospital in Dublin, and we were delighted to have installed an SRT unit there during recent weeks. We believe Ireland holds excellent promise for SRT, with 600 people diagnosed with non-melanoma skin cancer each day. We also sold an SRT-100 System to a hospital in Guatemala as we advance our efforts in Latin America.

“Our plan is to enter three to four new territories over the coming years, and we are advancing this goal with sales to Southeast Asia and Latin America, in addition to the UK and Ireland. We are regaining momentum in China now that pandemic lockdowns have been lifted and shipped two SRT systems there during the second quarter, for a total of five shipments to Asia so far this year.

“Sentinel IT is our HIPAA-compliant software that stores patient data for multiple clinical purposes and will include artificial intelligence to allow customers to better manage their practices and data. Sentinel IT is expected to play a key role in our growth, and during the quarter we launched our Sentinel/Sensus Cloud capabilities at the American Academy of Dermatology Annual Meeting. We look forward to showcasing Sentinel IT and our SRT products at local dermatology trade shows, as well as at the American Society for Radiation Oncology beginning October 1st. Although the hospital market has a longer sales cycle, radiation oncology is a highly attractive opportunity as their interest expands to skin cancer.”

Mr. Sardano concluded, “With an estimated one in five Americans, or 70 million people expected to develop skin cancer during their lifetime, SRT is the No. 1 choice for the non-invasive treatment of non-melanoma skin cancer. SRT treatments surpassed 480,000 in the last two years alone and the ROI for our premium SRT system under our fair market value leasing program continues to be compelling, with breakeven at only 2 to 2.5 patients per month. Surveys of Medicare show that SRT has experienced a 27% treatment growth rate year over year for the past six years. If this growth utilization rate continues at its current pace, SRT will soon become the treatment of choice for non-melanoma skin cancer. Accordingly, professional interest in SRT remains high, and we expect to meet our objectives of shipping at least 60 SRT systems during 2023 and returning to profitability in the second half of the year.”

Second Quarter Financial Results

Revenues for the second quarter of 2023 were $4.5 million, compared with $12.1 million for the second quarter of 2022. The decrease was primarily due to a lower number of SRT units sold as customers continued to defer purchases, as well as to lower sales to a large customer.

Cost of sales was $1.9 million for the second quarter of 2023, compared with $3.8 million for the prior-year quarter. The decrease was primarily due to lower sales in the second quarter of 2023.

Gross profit for the second quarter of 2023 was $2.6 million, or 57.9% of revenues, compared with $8.3 million, or 68.3% of revenues, for the second quarter of 2022. The decrease was primarily due to the lower number of units sold and higher costs charged by vendors in the 2023 quarter.

Selling and marketing expense was $1.6 million for the second quarter of 2023, compared with $1.7 million for the prior-year quarter. The decrease was primarily attributable to a decrease in marketing initiatives and commissions, partially offset by an increase in headcount costs.

General and administrative expense was $1.3 million for the second quarter of 2023, compared with $1.1 million for the second quarter of 2022. The increase was primarily due to higher professional fees, offset by a reduction in insurance expense.

Research and development expense was $0.8 million for the second quarter of 2023, unchanged from the comparable 2022 period.

Other income of $0.2 million for the second quarter of 2023 was related to interest income.

Net loss for the second quarter of 2023 was $0.4 million, or $0.02 per share, compared with net income of $3.5 million, or $0.21 per diluted share, for the second quarter of 2022.

Adjusted EBITDA for the second quarter of 2023 was negative $1.0 million, compared with positive $4.7 million for the second quarter of 2022. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided.

Cash and cash equivalents were $20.1 million as of June 30, 2023, compared with $25.5 million as of December 31, 2022. The Company had no outstanding borrowings under its revolving line of credit as of June 30, 2023 or December 31, 2022. Prepaid and other current assets were $8.1 million as of June 30, 2023, compared with $6.9 million as of December 31, 2022. Inventories were $10.1 million as of June 30, 2023, compared with $3.5 million as of December 31, 2022, with the increase reflecting the Company’s expectations for higher unit sales during the second half of the year.

Six Month Financial Results

Revenues were $7.9 million for the first half of 2023, compared with $22.4 million for the first half of 2022, reflecting a lower number of units sold.

Cost of sales was $3.7 million for the first half of 2023, compared with $7.0 million for the first half of 2022. The decrease was primarily related to lower sales in the first half of 2023.

Gross profit was $4.2 million for the first half of 2023, or 53.4% of revenues, compared with $15.4 million, or 68.7% of revenues, for the first half of 2022. The decrease in gross profit was primarily driven by the lower number of units sold and higher costs charged by vendors in the first half of 2023.

Selling and marketing expense was $3.7 million for the first half of 2023, compared with $2.9 million for the first half of 2022. The increase was primarily attributable to an increase in tradeshow expense and headcount costs, partially offset by a decrease in commissions.

General and administrative expense was $2.7 million for the first half of 2023, compared with $2.4 million for the first half of 2022. The increase was primarily due to higher professional fees, offset by a reduction in insurance expense.

Research and development expense was $1.9 million for the first half of 2023, compared with $1.6 million for the first half of 2022. The increase was primarily due to expenses related to a project to develop a drug-delivery system for aesthetic use. The Company expects to complete this project by the end of 2023.

Other income of $0.5 million for the first half of 2023 was related to interest income. Other income of $12.8 million for the first half of 2022 was related to the gain on the sale of a non-core asset.

Net loss for the first half of 2023 was $2.3 million, or $0.14 per share, compared with net income of $19.6 million, or $1.17 per diluted share, for the first half of 2022. Net income for the 2022 period includes a $12.8 million gain on the sale of a non-core asset.

Adjusted EBITDA for the first half of 2023 was negative $3.7 million, compared with positive $21.5 million for the first half of 2022.

Use of Non-GAAP Financial Information

This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

         
SENSUS HEALTHCARE, INC.
GAAP TO NON-GAAP RECONCILIATION
(unaudited)
                 
    For the Three Months Ended   For the Six Months Ended
    June 30,   June 30,
(in thousands)    2023     2022     2023     2022 
                 
Net income, as reported   $ (380 )   $ 3,524     $ (2,274 )   $ 19,586  
Add:                
      Depreciation and amortization     84       74       155       166  
      Stock compensation expense     67       40       209       97  
      Income tax expense (benefit)     (502 )     1,070       (1,303 )     1,718  
      Interest income, net     (245 )     (24 )     (488 )     (27 )
Adjusted EBITDA, non GAAP   $ (976 )   $ 4,684     $ (3,701 )   $ 21,540  
                 

Conference Call and Webcast

Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss financial results for the 2023 second quarter, provide a business update and answer questions. To access the conference call, dial 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). The call will be webcast live and can be accessed at this link, or in the Investors section of the Company’s website at www.sensushealthcare.com.

Following the conclusion of the conference call, a replay will be available until September 3, 2023 and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 8498645. An archived webcast of the call will also be available in the Investors section of the Company’s website.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100, SRT-100+ and SRT-100 Vision systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ”forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.

In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Contact:

LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]

(Tables to follow)

SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                   
    For the Three Months Ended   For the Six Months Ended  
(in thousands, except share and per share data)   June 30,   June 30,  
     2023     2022     2023     2022   
    (unaudited)   (unaudited)   (unaudited)   (unaudited)  
Revenues   $ 4,527     $ 12,080     $ 7,941     $ 22,417    
Cost of sales     1,908       3,824       3,700       7,013    
Gross profit     2,619       8,256       4,241       15,404    
Operating expenses:                  
Selling and marketing     1,595       1,728       3,693       2,946    
General and administrative     1,329       1,131       2,693       2,404    
Research and development     822       827       1,920       1,556    
Total operating expenses     3,746       3,686       8,306       6,906    
Income (loss) from operations     (1,127 )     4,570       (4,065 )     8,498    
Other income:                  
Gain on sale of assets                       12,779    
Interest income     245       24       488       27    
Other income     245       24       488       12,806    
Net Income (loss) before income tax     (882 )     4,594       (3,577 )     21,304    
Provision for (benefit from) income tax     (502 )     1,070       (1,303 )     1,718    
Net Income (loss)   $ (380 )   $ 3,524     $ (2,274 )   $ 19,586    
Net income (loss) per share      – basic   $ (0.02 )   $ 0.21     $ (0.14 )   $ 1.19    
                                                     – diluted   $ (0.02 )   $ 0.21     $ (0.14 )   $ 1.17    
Weighted average number of shares used in computing net income (loss) per share                
                                                     – basic
    16,249,766       16,495,043       16,247,567       16,508,629    
                                                     – diluted     16,249,766       16,631,478       16,247,567       16,710,550    
                   

SENSUS HEALTHCARE, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
               
    As of June 30,   As of December 31,  
(in thousands, except shares and per share data)   2023   2022  
    (unaudited)        
Assets              
Current assets              
Cash and cash equivalents   $ 20,053     $ 25,520    
Accounts receivable, net     9,149       17,299    
Inventories     10,131       3,501    
Prepaid and other current assets     8,059       6,921    
Total current assets     47,392       53,241    
Property and equipment, net     367       243    
Intangibles, net     1       50    
Deposits     24       24    
Deferred tax asset     3,017       1,713    
Operating lease right-of-use assets, net     866       996    
Other noncurrent assets     350       468    
Total assets   $ 52,017     $ 56,735    
Liabilities and stockholders’ equity              
Current liabilities              
Accounts payable and accrued expenses   $ 3,941     $ 5,521    
Product warranties     379       403    
Operating lease liabilities, current portion     181       190    
Income tax payable           890    
Deferred revenue, current portion     692       693    
Total current Liabilities     5,193       7,697    
Operating lease liabilities, net of current portion     698       830    
Deferred revenue, net of current portion     116       139    
Total liabilities     6,007       8,666    
Commitments and contingencies              
Stockholders’ equity              
Preferred stock, 5,000,000 shares authorized and none issued and outstanding              
Common stock, $0.01 par value – 50,000,000 authorized; 16,912,595 issued and 16,395,766 outstanding at June 30, 2023; 16,902,761 issued and 16,390,419 outstanding at December 31, 2022     169       169    
Additional paid-in capital     45,286       45,031    
Treasury stock, 516,829 and 512,342 shares at cost, at June 30, 2023 and December 31, 2022, respectively     (3,473 )     (3,433 )  
Retained earnings     4,028       6,302    
Total stockholders’ equity     46,010       48,069    
Total liabilities and stockholders’ equity   $ 52,017     $ 56,735